Alain Luts

Absolute and relative stability of alexithymia in alcoholic inpatients undergoing alcohol withdrawal : relationship to depression and anxiety

To evaluate whether alexithymia in alcohol-dependent patients is a personality trait or a state-dependent phenomenon related to depression and anxiety, we evaluated absolute stability (the extent to which alexithymia scores change over time) and relative stability (the extent to which relative differences among individuals remain the same over time) of alexithymia during alcohol withdrawal. Seventy alcohol-dependent inpatients were assessed for alexithymia, depression and anxiety with the 20-item Toronto Alexithymia Scale, the Beck Depression Inventory and the State-Trait Anxiety Inventory at the onset of withdrawal, after 2 days and 2 weeks. Paired t-tests and correlational analyses were performed to evaluate absolute and relative stability of alexithymia and hierarchical regression analyses to assess whether alexithymia was related to anxiety and depression. Alexithymia decreased significantly from onset to end of withdrawal, but two of its three subfactors remained stable. Alexithymia scores at onset correlated significantly with scores at end, after partialling out the effects of depression and anxiety. In conclusion, the relative stability of alexithymia contrasting with large decreases in depression and anxiety during alcohol withdrawal supports the view that alexithymia is a stable personality trait rather than a state-dependent phenomenon.

Insulin sensitivity, adjusted β-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study

Atypical antipsychotic drugs (AADs) induce weight gain and truncal adiposity, and even the metabolic syndrome (MetS), which may progress to IFG/IGT or DM. AAD effects in lean schizophrenic patients without MetS have not been documented, especially in terms of weight gain and changes in insulin sensitivity (S), beta-cell function (beta) and adiponectinaemia. We prospectively determined the effects of nine-month therapy with AADs on anthropometrics, metabolism and adiponectinaemia, including homoeostasis model assessment (HOMA) modelling of S, beta and betaxS (hyperbolic product, assessing individual beta adjusted for S). We analyzed 36 schizophrenic subjects (M/F: 24/12; Caucasian: n=23, North African: n=12, South Asian: n=1) aged 35+/- years (mean+/-one S.D.) free of MetS (NCEP-ATPIII), of whom 19 study completers were evaluated following AAD treatment. S, beta, betaxS and adiponectin were measured at zero, three and nine months. At nine months, BMI had risen from 22+/-2 to 25+/-2kg/m(2) (P<0.001) and waist circumference from 85+/-8 to 91+/-11cm (P<0.001), while adiponectin decreased from 10.4+/-5.1 to 7.4+/-3.8mug/mL (P<0.001). Blood pressure and lipids were unaffected. S decreased from 138+/-49 to 110+/-58% (P=0.006) and beta increased from 83+/-24 to 100+/-40% (P=0.034). As a result, betaxS decreased from 106+/-19 to 91+/-27% (P=0.015). Fasting glycaemia rose from 89+/-5 to 96+/-9mg/dL (P=0.007). On study completion, 21% had IFG. Long-term use of AADs in lean, drug-naive, schizophrenics initially free of MetS induced weight gain and truncal fat accumulation associated with decreases in adiponectin and hyperbolic product, explaining the increased fasting glycaemia and impaired fasting glucose seen in predisposed individuals.

Self-inflicted repetitive optic nerve injury: a case report.

Purpose To describe an obsessive-compulsive patient who developed blindness after self-inflicted repetitive optic nerve injury. Methods Case report. Results A myopic 46-year-old male became blind as a result of intermittent rubbing of his eyes, causing stretching of the optic nerves. Extensive ocular, neurologic and systemic work-ups were negative. Cerebral and orbital MR studies showed severe bilateral optic nerve atrophy. Psychiatric evaluation confirmed obsessive-compulsive personality. Conclusions Self-inflicted optic nerve injury should be included in the differential diagnosis of progressive optic neuropathy in a young adult.